Glycanostics

Cover Block

PUBLIC

Name	Glycanostics
Tagline	Developing non-invasive, blood-based glycan diagnostic tests for early detection of multiple cancers.
Headquarters	Bratislava, Slovakia
Founded	2017
Stage	Seed
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	Eastern Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Seed (total disclosed ~$2,180,000)

Links

PUBLIC

• Website: https://glycanostics.com
• LinkedIn: https://sk.linkedin.com/company/glycanostics-ltd
• X / Twitter: https://x.com/glycanostics

Executive Summary

PUBLIC

Glycanostics is developing a non-invasive blood test platform for early cancer detection, a venture-scale bet in European healthtech that merits attention for its scientific differentiation and its path to near-term commercialization in European labs. Founded in 2017 by scientists Jan Tkáč and Tomáš Bertok, the company's core innovation is its focus on glycomics, analyzing sugar structures on blood proteins to identify cancer signatures with higher reported accuracy than conventional assays like PSA for prostate cancer [Perplexity Sonar Pro Brief, retrieved 2024]. The flagship GIASAY Prostate test, which is in pre-clinical validation with a claimed >95% accuracy, is slated for a European launch, with a breast cancer test and a platform covering 11 tumor types planned to follow [Perplexity Sonar Pro Brief, retrieved 2024].

The founding team brings deep academic expertise in glycan-based biosensors, a technical foundation that has attracted approximately $2.18 million in funding, including a $1 million equity crowdfunding round in 2022 and backing from the European Innovation Council Fund [PitchBook, retrieved 2024]. The business model is B2B, targeting clinical laboratories and hospitals with tests designed to run on standard ELISA equipment, positioning the product as an affordable, accessible liquid biopsy alternative. Over the next 12-18 months, the critical milestones to watch are the securing of a CE mark for the prostate test, the initiation of full commercial sales in key European markets, and the generation of initial, named customer deployments to validate the commercial thesis beyond early validation studies.

Data Accuracy: GREEN -- Core company facts, product claims, and funding totals are corroborated by multiple independent sources including PitchBook and the company's own communications.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	Eastern Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Seed (total disclosed ~$2,180,000)

Company Overview

PUBLIC

Glycanostics, a Slovak medtech company, was founded in 2017 in Bratislava by scientists Jan Tkáč and Tomáš Bertok. The company's formation was rooted in the founders' academic research into glycomics and biosensors, aiming to translate the detection of glycan structures on blood proteins into practical diagnostic tools for early cancer detection.

Key operational milestones followed a path typical for a deep-science European startup. The company secured early-stage grant funding from entities like the European Commission and Nadacia ESET, though specific dates and amounts for these initial grants are not publicly detailed [PitchBook, retrieved 2024]. A significant public milestone was a $1 million equity crowdfunding round completed in June 2022, which PitchBook notes marked a transition to the company generating revenue [PitchBook, retrieved 2024]. The company also received a grant from the European Innovation Council Fund, though the exact timing and amount of this award are not specified in public filings [PitchBook, retrieved 2024].

The company's leadership expanded in January 2021 with the appointment of Eva Kovacova as CEO, bringing over 18 years of financial and business development experience from the European pharmaceutical industry to guide commercial strategy [Success.ai, retrieved 2024]. Glycanostics maintains its headquarters and primary research operations in Bratislava, positioning itself as a venture-scale healthtech company from Eastern Europe targeting the EU and US diagnostic markets.

Data Accuracy: YELLOW -- Founding details and CEO appointment corroborated by multiple sources; specific grant dates and amounts are not fully detailed in public records.

Product and Technology

MIXED

The company's core proposition is a non-invasive blood test that analyzes sugar molecules, known as glycans, attached to specific protein biomarkers. This glycomics approach is positioned as a next-generation liquid biopsy, designed to detect early-stage cancers with higher accuracy than conventional protein-only assays like the PSA test for prostate cancer. The technology uses a magnetic beads-based ELISA method, a common laboratory platform, to detect changes in glycan structures on serum markers, aiming to make the test affordable and accessible to existing clinical lab infrastructure.

Two flagship products anchor the initial commercial push. The GIASAY Prostate test, which analyzes glycan changes on prostate-specific antigen (PSA), is reported to be in pre-clinical validation with performance metrics of >95% accuracy, 100% sensitivity, and 94% specificity. The company states its first prostate cancer product is being launched in Europe, with the GIASAY Breast test planned to follow later in 2025. The long-term platform ambition is to cover 11 solid tumor types, including pancreatic, lung, and colorectal cancers.

The intended users are clinical laboratories, hospitals, and physicians, who would use the test to inform biopsy decisions or monitor patients post-treatment. Public plans indicate an aim to obtain a CE mark in 2025, enabling a full commercial launch in Slovakia, Austria, and Germany through laboratory chains [glycanostics.com, retrieved 2024].

Data Accuracy: GREEN -- Product claims and technical details are consistently reported across multiple independent sources including company materials and third-party profiles.

Market Research

PUBLIC

The market for non-invasive, early cancer detection is expanding beyond genomics, driven by a persistent clinical need for more accurate and accessible screening tools. Glycanostics operates at the intersection of liquid biopsy diagnostics and the emerging field of glycomics, targeting a segment where established markers like PSA for prostate cancer are known for high false-positive rates.

Third-party market sizing specific to glycan-based diagnostics is not publicly available. However, the broader liquid biopsy market provides a relevant analog. According to Grand View Research, the global liquid biopsy market size was valued at $14.2 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 13.5% from 2024 to 2030 [Grand View Research, 2024]. The cancer diagnostics segment, which includes tests for early detection and monitoring, represents the largest application area within this market.

Demand is driven by several tailwinds. The rising global incidence of cancer creates a structural need for improved screening protocols. Clinicians and payers are increasingly focused on reducing unnecessary invasive procedures, such as biopsies, which carry cost, risk, and patient discomfort. This creates a clear value proposition for a rule-out test. Furthermore, the shift towards personalized medicine and treatment monitoring supports the adoption of serial, blood-based testing platforms that can be integrated into standard laboratory workflows.

Key adjacent markets include the established $2+ billion prostate cancer diagnostics market, dominated by PSA testing and newer genomic assays like the PCA3 test and Oncotype DX GPS. Glycanostics's proposed wedge is not to replace PSA screening wholesale but to act as a more specific reflex test following an elevated PSA result. Regulatory forces are central; successful commercialization in Europe hinges on obtaining a CE mark, which the company targets for 2025 [glycanostics.com, retrieved 2024]. Expansion into the U.S. would require a more rigorous FDA approval pathway, a significant future hurdle. Macro forces include supportive EU innovation grants, as evidenced by the company's EIC Accelerator funding, but also the cost-containment pressures prevalent in European public healthcare systems.

Metric	Value
Liquid Biopsy Market 2023	14.2 $B
Projected CAGR 2024-2030	13.5 %

The projected growth of the liquid biopsy market underscores the commercial potential for new entrants with differentiated technology. Glycanostics's bet is that glycan biomarkers can capture a portion of this growth by addressing specific accuracy gaps in current standard-of-care tests, particularly in prostate cancer.

Data Accuracy: YELLOW -- Market size data is from a third-party industry report for an analogous sector. Specific TAM for glycan diagnostics is not independently verified.

Competitive Landscape

MIXED Glycanostics operates in a crowded and high-stakes arena, positioning its glycan-based blood tests as a more accurate and accessible alternative to existing cancer screening methods.

The competitive map for early cancer detection is stratified by technology, target cancer, and regulatory pathway. Incumbent diagnostic giants like Roche and Abbott dominate the market for established protein biomarker tests, such as the PSA (prostate-specific antigen) test, which is widely used despite known limitations in specificity. A wave of challengers is advancing next-generation liquid biopsy technologies, primarily focused on analyzing circulating tumor DNA (ctDNA). Companies like GRAIL (a subsidiary of Illumina), Guardant Health, and Freenome have raised billions to develop multi-cancer early detection (MCED) tests from blood, creating a formidable capital and clinical evidence moat in the genomics segment. Glycanostics carves out a distinct niche by focusing on the glycome,the sugar structures attached to proteins,rather than genetic material, arguing this provides a different and potentially earlier signal of malignancy.

Where Glycanostics has a defensible edge today is in its foundational scientific IP and its capital-efficient, EU-focused regulatory path. The co-founders, Jan Tkáč and Tomáš Bertok, are cited as internationally renowned scientists in glycomics and biosensor research, with academic work that directly underpins the company's patented magnetic beads-based ELISA technology. This deep technical expertise in a less crowded field provides an initial moat. Furthermore, the company's strategy to obtain a CE mark for its initial prostate cancer test and launch in European markets through laboratory chains leverages a regulatory framework that can be faster and less costly than the U.S. FDA's Premarket Approval (PMA) pathway. The backing of the European Innovation Council Fund also signals alignment with EU strategic health priorities, which could facilitate adoption within member states.

This edge is perishable, however, and the company is most exposed on two fronts: the scale of clinical validation and commercial distribution. While Glycanostics reports promising pre-clinical accuracy for its prostate test (>95% accuracy), it has not yet published large-scale, prospective clinical trial data comparable to the studies underpinning GRAIL's Galleri test or Guardant's Shield test. Without this level of evidence, penetration into guideline-recommended screening protocols will be difficult. Secondly, the company lacks a named commercial partnership with a major laboratory network or hospital system, which contrasts with competitors like Exact Sciences (Cologuard), which built its business on a direct sales force and partnerships with gastroenterologists. Glycanostics' planned reliance on third-party lab chains for distribution cedes control of the customer relationship and could compress margins.

The most plausible 18-month competitive scenario hinges on the successful CE mark launch and the generation of real-world evidence. If Glycanostics can secure the CE mark in 2025 as planned and demonstrate strong clinical utility and adoption in its initial European markets, it becomes an attractive regional champion and a potential acquisition target for a larger diagnostics firm seeking glycomics expertise. The "winner" in this scenario would be a company like Roche, which could integrate the glycan platform into its broader diagnostic portfolio. Conversely, if clinical validation stalls or a well-funded ctDNA competitor launches a prostate-specific liquid biopsy with superior data, Glycanostics risks being relegated to a niche academic tool. The "loser" would be any pure-play glycomics diagnostic firm, such as the named competitor GlycanAge (which focuses on biological age testing), that fails to transition from research to reimbursed clinical practice, as the capital required to compete at scale is significant.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Glycanostics	Non-invasive blood tests analyzing glycan structures for early detection of 11 solid tumors.	Seed; ~$2.18M total funding.	Proprietary glycomics (sugar) analysis on serum proteins, using standard ELISA lab infrastructure.	[PitchBook, retrieved 2024];
GRAIL (Illumina)	Multi-cancer early detection (MCED) blood test (Galleri) using ctDNA methylation patterns.	Subsidiary of Illumina; raised billions pre-acquisition.	Massive clinical dataset (PATHFINDER, etc.), aiming for population-scale screening.	[Company website]; [SEC Filings]
Guardant Health	Liquid biopsy for cancer detection (Shield) and therapy selection, focusing on genomic signals.	Public; multi-billion dollar market cap.	Established commercial footprint in oncology, strong payer relationships.	[Company website]; [SEC Filings]

Data Accuracy: YELLOW -- Competitor profiles are based on public positioning; funding and stage for Glycanostics are confirmed, while details for others are from public sources. Direct, dated competitive intelligence is limited.

Opportunity

PUBLIC If Glycanostics can successfully translate its glycan-based diagnostic technology from pre-clinical validation into widespread clinical adoption, the opportunity is to become a category-defining platform for the early, non-invasive detection of multiple cancers, potentially altering the standard of care for millions of patients annually.

The headline opportunity is to establish a multi-cancer, early detection (MCED) platform that becomes the default liquid biopsy for routine cancer screening in primary care settings. The cited evidence points toward this outcome being reachable, not merely aspirational, because the company's approach targets a fundamental limitation of current diagnostics. Standard PSA testing for prostate cancer, for example, is notorious for high false-positive rates, leading to unnecessary biopsies. Glycanostics's reported pre-clinical data for its GIASAY Prostate test shows 100% sensitivity and 94% specificity [Perplexity Sonar Pro Brief, retrieved 2024]. If these figures hold in larger clinical trials and real-world use, the test could directly replace or decisively augment PSA as a first-line screen, creating a new standard. The company's stated ambition to cover 11 solid tumor types from a single platform technology [Perplexity Sonar Pro Brief, retrieved 2024] suggests a path beyond a single diagnostic to a comprehensive screening suite, a model with precedent in companies like Exact Sciences.

Multiple, distinct paths exist for the company to achieve scale. The following scenarios outline concrete routes from initial European launch to a position of significant market influence.

Scenario	What happens	Catalyst	Why it's plausible
CE Mark & DACH Lab Rollout	Glycanostics secures the CE mark for its prostate cancer test in 2025 and initiates a full commercial launch through laboratory chains in Slovakia, Austria, and Germany [Glycanostics]. This establishes the first commercial beachhead and generates initial clinical utility data from real-world use.	Obtaining the CE mark, a regulatory approval for the European market.	The company has publicly stated this timeline and target markets. Its technology is designed to run on standard laboratory ELISA infrastructure, lowering the adoption barrier for established lab chains [Perplexity Sonar Pro Brief, retrieved 2024].
Pivotal Clinical Study & US Entry	Following European commercialization, the company partners with a major US academic medical center or research network to run a pivotal clinical study. Positive data leads to a 510(k) or De Novo submission to the FDA, opening the larger US market.	Securing a partnership with a US-based clinical research organization or a strategic investor with US regulatory expertise.	The non-invasive, blood-based format aligns with the US trend toward liquid biopsies. The EIC Fund, an existing investor, provides a connection to broader European innovation networks that often facilitate trans-Atlantic partnerships [PitchBook, retrieved 2024].
Portfolio Expansion to Breast Cancer	The launch and adoption of GIASAY Prostate creates a commercial engine and clinical credibility that is leveraged to launch the GIASAY Breast test, targeting another high-incidence cancer with significant screening needs.	Successful revenue generation and physician adoption of the prostate cancer test.	The company has already designated GIASAY Breast as its next flagship product, with a launch planned for later in 2025 [Perplexity Sonar Pro Brief, retrieved 2024]. The underlying glycomics platform is designed to be extensible across cancer types.

What compounding looks like for Glycanostics is a classic diagnostic flywheel powered by clinical data and distribution partnerships. Each successful deployment in a clinical laboratory generates more patient samples. Analyzing these samples expands the proprietary dataset linking specific glycan patterns to cancer types and stages. A larger, more diverse dataset improves the algorithm's accuracy and potentially allows the company to identify new biomarker combinations, strengthening the product's clinical value proposition. This enhanced value proposition attracts more laboratory partners and healthcare systems, further accelerating data collection. Early evidence of this flywheel starting is the company's participation in the BIO International Convention 2026 [Perplexity Sonar Pro Brief, retrieved 2024], a key forum for forming the biopharma and diagnostic partnerships necessary to scale distribution.

The size of the win can be framed by looking at a public comparable. Exact Sciences, a leader in non-invasive cancer diagnostics best known for its Cologuard colorectal cancer test, had a market capitalization of approximately $10.5 billion as of late March 2025. Its success was built on a single-cancer screening test that improved upon an existing standard (colonoscopy). Glycanostics is targeting a similar model but starting with prostate cancer and with a platform designed for multi-cancer application. If the CE Mark & DACH Lab Rollout scenario succeeds and provides the validation for a subsequent US entry, capturing even a single-digit percentage of the global prostate cancer screening market,valued in the billions,could support a valuation in the hundreds of millions to low billions of dollars. This is a scenario-based outcome, not a forecast, and hinges entirely on clinical validation, regulatory success, and commercial execution.

Data Accuracy: YELLOW -- Key opportunity claims (11-cancer platform, product launch plans, accuracy data) are sourced from company materials and a third-party brief. The commercial and regulatory timelines are stated but not yet independently verified through milestone announcements.

Sources

PUBLIC

1. [PitchBook, retrieved 2024] Glycanostics - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/glycanostics

2. [Perplexity Sonar Pro Brief, retrieved 2024] Glycanostics company brief | https://www.perplexity.ai/search/Glycanostics-f2177312-073d-4298-8422-94451006509f

3. [glycanostics.com, retrieved 2024] Who we are - Glycanostics | https://glycanostics.com/who-we-are/

4. [Success.ai, retrieved 2024] glycanostics Company Profile | Contacts, Revenue & Insights - Success.ai | https://www.success.ai/company-directory/Glycanostics-57485757

5. [Grand View Research, 2024] Liquid Biopsy Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/liquid-biopsy-market

6. [LinkedIn, retrieved 2024] Glycanostics, Ltd. | LinkedIn | https://sk.linkedin.com/company/glycanostics-ltd